

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Medical technologies evaluation programme

### Equality impact assessment: Guidance development

#### MT380 UrgoStart for treating leg ulcers and diabetic foot ulcers

The impact on equality has been assessed during this evaluation according to the principles of the [NICE Equality scheme](#).

#### Medical technology consultation document

1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how?

No equality issues were raised during the scoping process. This dressing is used to treat people with leg and / or diabetic foot ulcers. Women are 2 times more likely to have a leg ulcer than men. 1 in 10 people with diabetic foot ulcers will have an amputation. Leg ulcers and diabetic foot ulcers may be associated with other disabilities. Age, sex and disability are all protected characteristics under the 2010 Equality Act.

2. Have any other potential equality issues been highlighted in the sponsor's submission, or patient organisation questionnaires, and, if so, how has the committee addressed these?

No action required.

3. Have any other potential equality issues been identified by the committee and, if so, how has the committee addressed these?

No action required.

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to or difficulties with access for the specific group?

No

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No.

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

Not applicable.

7. Have the committee's considerations of equality issues been described in the medical technology consultation document, and, if so, where?

Not applicable.

**Approved by Acting Programme Director: Mark Campbell**

**Date: 9 October 2018**

## Medical technology guidance document

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the committee addressed these?

During consultation, patient representatives highlighted the disproportionate burden of chronic wounds and the need therefore for effective interventions. The committee decided to revise its considerations to reflect these comments.

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to access for the specific group?

No

3. If the recommendations have changed after consultation, is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

N/A

5. Have the committee's considerations of equality issues been described in the medical technology guidance document, and, if so, where?

Yes. Section 4.3.

**Approved by Acting Programme Director:** Mark Campbell

**Date:** 31 January 2019